Hyperliquid Strategies has expanded its equity financing facility with Chardan Capital Markets from $1 billion to $2.5 billion, according to a new filing with the U.S. Securities and Exchange Commission (SEC) dated Sept. 1.
The Nasdaq-listed company can raise capital over time by selling newly issued $PURR shares to Chardan. Hyperliquid Strategies previously said proceeds could support general corporate purposes, including potential purchases of $HYPE, the native token of the Hyperliquid network.
However, the $2.5 billion figure represents the facility’s maximum aggregate capacity. It does not mean Hyperliquid Strategies has received that amount, completed an offering of that size or committed the proceeds to buying $HYPE.
Actual proceeds will depend on the number of shares sold and the prices at which transactions occur. Each issuance would increase $PURR’s outstanding share count, potentially diluting existing investors.
Hyperliquid Strategies adds $1.5 billion to equity facility
Hyperliquid Strategies and Chardan signed an amendment to their ChEF purchase agreement on Sept. 1. The original agreement was dated Oct. 22, 2025.
The amendment increases the total commitment by $1.5 billion. Under the agreement, Chardan can purchase newly issued common shares from Hyperliquid Strategies after the company submits qualifying purchase notices.
Today we filed an 8K explaining the details of our updated equity facility.When we originally put this facility in place it had a headline of $1bn (which at the time seemed like an awful lot). We are now close to hitting the $1bn limit, so we have increased the agreement to…
— David Schamis, Sept. 1, 2026
Hyperliquid Strategies controls the timing and amount of individual share sales. Its SEC disclosures state that financing decisions will depend on market conditions, $PURR’s trading price and management’s assessment of how the proceeds should be used.
The arrangement differs from a traditional loan because share sales do not create principal repayments or interest expenses. The company does, however, exchange equity for cash, reducing the percentage ownership represented by each existing share.
The facility also does not guarantee that Chardan will purchase $2.5 billion in stock. Transactions remain subject to the agreement’s terms, conditions and limitations, meaning the amount ultimately raised could be lower than the maximum commitment.
Potential $HYPE purchases remain optional
Hyperliquid Strategies said in its prospectus that proceeds from equity-facility sales were intended for general corporate purposes, including potential $HYPE purchases.
The language gives management broad discretion. It does not establish a minimum allocation for $HYPE, a purchasing deadline or a fixed token target. Proceeds could also be directed toward operating expenses, transaction costs or other corporate needs.
The Sept. 1 Form 8-K does not report a new $HYPE acquisition. It also does not disclose whether Hyperliquid Strategies has completed share sales using the additional $1.5 billion in capacity.
Hyperliquid Strategies reported holding 29.3 million $HYPE as of Aug. 19. Since completing its business combination in December 2025, the company had spent $773.4 million to acquire approximately 16.5 million tokens at an average price of $46.77, as crypto.news reported.
The company also reported $149.9 million in cash at the end of June and said it carried no debt. Its $HYPE holdings had more than doubled from the approximately 12.6 million tokens associated with the company’s creation.
The transaction that formed Hyperliquid Strategies included $305 million in cash alongside the initial $HYPE contribution. The company has since used equity financing as a central part of its token accumulation strategy.
Nasdaq rules limit lower-priced share sales
The amendment introduces an exchange cap that becomes relevant after aggregate share sales through the facility reach $1 billion.
After that threshold, Hyperliquid Strategies generally cannot sell more than 42,641,847 shares at prices below $12.02. The limit equals 19.99% of the common shares outstanding immediately before the amendment was executed.
The company can exceed the cap if shareholders approve additional issuances under Nasdaq rules. The restriction may also cease to apply if shareholder approval is not required under an available Nasdaq provision.
At $12.02 per share, 42,641,847 shares would represent approximately $512.5 million in gross proceeds. The calculation excludes fees and assumes every share is sold at the stated price.
The relationship between the share cap and the expanded commitment could restrict access to the full facility when $PURR trades below $12.02. Raising the entire $2.5 billion may require higher sale prices, shareholder approval or an applicable Nasdaq exception.
The effect on existing investors will depend on the timing and size of each issuance. Selling shares at lower prices requires the company to issue more stock to raise the same amount of cash, increasing potential dilution.
$PURR closes below the amendment’s threshold
$PURR closed at $11.36 on Sept. 1, down approximately 7.3% during regular trading. The stock opened at $11.76 and traded between $11.03 and $12.31. Trading volume reached approximately 24.3 million shares.
Source: Google Finance
The closing price placed $PURR below the amendment’s $12.02 reference level. However, the market price does not activate the exchange cap by itself. The restriction concerns completed below-threshold sales after cumulative facility purchases reach $1 billion.
